FDA Accepts Application for Merck's KEYTRUDA® Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Life Science Investing
AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year Pharmaceutical Investing
Gilead Sciences: 4 Questions: Global Experts Convene To Identify Key Measures to Long-Term Success in HIV Pharmaceutical Investing
EMD Electronics Expands Semiconductor Manufacturing Capacities for the World's Largest Integrated Specialty Gases Facility in Hometown, Pennsylvania Life Science Investing
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office Pharmaceutical Investing
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® Plus LENVIMA® In Certain Patients With Advanced Melanoma and Metastatic Colorectal Cancer Life Science Investing
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda , Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection Life Science Investing
